<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01516788</url>
  </required_header>
  <id_info>
    <org_study_id>814860</org_study_id>
    <nct_id>NCT01516788</nct_id>
  </id_info>
  <brief_title>Photoprovocation Testing in Subjects With Cutaneous Lupus</brief_title>
  <official_title>Photoprovocation Testing in Subjects With Cutaneous Lupus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Photosensitivity is well documented among lupus patients and is one of the diagnostic&#xD;
      criteria for systemic lupus erythematosus (SLE). Photosensitivity is highly prevalent in&#xD;
      lupus and has a wide range of clinical presentations. However, photosensitivity is a poorly&#xD;
      defined in lupus and its pathogenesis is not well understood. The purpose of this study is to&#xD;
      characterize the early clinical and histopathological changes in lupus skin that occur as a&#xD;
      response to ultraviolet light.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">July 2, 2018</completion_date>
  <primary_completion_date type="Actual">July 2, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The change from baseline of the neutrophil and inflammasome response to ultraviolet radiation at 24 hours.</measure>
    <time_frame>24 hours and 48 hours</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Lupus Erythematosus</condition>
  <condition>Photosensitivity Conditions</condition>
  <arm_group>
    <arm_group_label>Phototesting</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Phototesting</intervention_name>
    <description>Single MED dose on Day 2</description>
    <arm_group_label>Phototesting</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants who have a diagnosis of CLE based on either the Gilliam classification of&#xD;
             DLE and SCLE, or SLE based on the American College of Rheumatology criteria.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Participants who do not meet criteria for either CLE or SLE.&#xD;
&#xD;
          2. Participants with a diagnosis of Erythropoietic Protoporphyria and Solar Urticaria, or&#xD;
             another photodermatoses other than Polymorphous light eruption.&#xD;
&#xD;
          3. Participants who are not yet 18 years old or who are not capable of giving written&#xD;
             informed consent prior to enrolling in the study.&#xD;
&#xD;
          4. Participants who have undergone any recent phototesting, or phototherapy exposure, or&#xD;
             those who are suspected of having a drug-induced photosensitivity.&#xD;
&#xD;
          5. Female participants who are pregnant or breastfeeding will be excluded from the study.&#xD;
             This will be determined by patient self-reporting.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>January 12, 2012</study_first_submitted>
  <study_first_submitted_qc>January 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 25, 2012</study_first_posted>
  <last_update_submitted>July 12, 2021</last_update_submitted>
  <last_update_submitted_qc>July 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

